Equities

Aptose Biosciences Inc

Aptose Biosciences Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.4052
  • Today's Change0.005 / 1.27%
  • Shares traded158.82k
  • 1 Year change-86.17%
  • Beta1.2461
Data delayed at least 15 minutes, as of Sep 27 2024 20:56 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Aptose Biosciences Inc. is a clinical-stage biotechnology company engaged in developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. Its lead clinical-stage compound Tuspetinib (TUS), is an oral kinase inhibitor that has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. Its Luxeptinib (LUX) is being developed for the treatment of patients with certain B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and certain non-Hodgkin’s lymphomas (NHL) who are resistant or intolerant to conventional treatments.

  • Revenue in USD (TTM)0.00
  • Net income in USD-40.29m
  • Incorporated2006
  • Employees35.00
  • Location
    Aptose Biosciences Inc251 Consumers Rd Suite 1105NORTH YORK M2J 4R3CanadaCAN
  • Phone+1 (647) 479-9828
  • Fax+1 (416) 798-2200
  • Websitehttps://aptose.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
GT Biopharma Inc0.00-11.35m4.67m2.00--0.848-----7.72-7.720.002.470.00----0.00-82.84-205.36-120.73--------------0.00------63.62------
Silo Pharma Inc72.12k-3.45m4.75m3.00--0.662--65.91-1.16-1.180.02421.600.0079----24,040.00-37.69-24.90-43.50-26.3991.9082.79-4,777.02-2,757.85----0.00--0.00--7.07------
Titan Pharmaceuticals Inc4.00k-5.46m4.81m4.00--1.20--1,202.22-6.59-6.590.00494.370.0016--0.17021,000.00-211.58-96.80-368.99-156.65-----136,525.00-406.26---309.960.00---66.97-51.1645.43---65.61--
AgriFORCE Growing Systems Ltd57.60k-15.05m4.90m7.00--0.3866--85.01-5.81-5.810.00370.13430.0034--1.218,228.57-88.79-78.95-124.14-109.8617.86---26,121.49-243,182.501.24-1.280.0789------8.85--48.61--
CYANOTECH CORP23.82m-5.10m5.37m77.00--0.5026--0.2253-0.7549-0.75493.561.530.88952.0512.12309,389.60-19.04-3.46-29.60-4.4624.7234.54-21.41-3.580.3354-6.610.377---0.4616-5.24-53.11---6.42--
Stemtech Corp5.37m-5.11m5.59m45.00------1.04-0.0518-0.05180.0529-0.03591.338.3942.31---126.26------77.87---95.16--0.065-2.59----7.94--36.45------
Hoth Therapeutics Inc0.00-7.46m6.08m2.00--0.5049-----1.69-1.690.001.740.00----0.00-67.99-157.07-76.33-177.32------------0.00------31.01------
Coeptis Therapeutics Holdings Inc0.00-16.14m6.44m5.00---------0.5143-0.51430.00-0.01110.00----0.00-284.35-37.29-709.12-38.23------------1.22------43.40------
Bon Natural Life Ltd29.52m4.60m6.55m96.000.33060.05461.190.22194.994.9932.1030.230.704515.275.19307,524.6010.8614.0413.6920.6829.9430.0015.4217.622.4130.540.09550.00-1.2922.32-26.3283.09-6.70--
Biofrontera Inc35.24m-13.51m6.98m85.00--0.5883--0.1982-5.29-5.2912.122.141.211.977.27414,623.50-46.20---113.24--47.75---38.33--1.46-3.530.0264--18.82---3,045.47------
Aptose Biosciences Inc0.00-40.29m7.25m35.00---------4.45-4.450.00-0.12020.00----0.00-214.76-63.94-627.58-71.96---------------------22.44---38.48--
Guardion Health Sciences Inc6.43m-5.93m7.49m9.00--0.5445--1.16-4.614.975.0410.710.44672.748.20714,121.10-41.22-77.90-45.86-86.5544.8642.45-92.26-176.9316.59-2.980.00--10.8567.03101.00---58.56--
Integrated BioPharma, Inc.50.32m112.00k7.52m147.0094.660.39116.980.14950.00260.00261.620.63911.954.3210.96342,292.500.433813.150.550519.977.7211.220.22265.871.08--0.0004---0.70060.1357806.25-41.775.96--
Lotus Pharmaceuticals Inc70.79m1.72m7.81m233.000.05240.00082.030.11040.05530.05532.563.580.632137.2717.85303,836.901.5522.841.7126.4035.1041.622.4519.930.442830.800.05160.0028.7131.70-12.2251.1170.48--
CV Sciences Inc15.85m-2.53m8.38m42.00--3.34--0.529-0.0157-0.01570.0980.01391.691.5525.35377,285.70-26.94-43.42-73.44-77.7546.0651.81-15.95-45.680.2530--0.0114---1.24-19.80133.96-20.87----
Data as of Sep 27 2024. Currency figures normalised to Aptose Biosciences Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.